Sorry, you need to enable JavaScript to visit this website.

Study Looking at Safety of Dacomitinib and How it Works in the Body in People with Livers that Do Not Work Properly

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Plasma Pharmacokinetics and Safety of Dacomitinib in Participants With Severely Impaired Hepatic Function Relative to Participants With Normal Hepatic Function

Category & Conditions: Cancer
Medicine: VIZIMPRO® TABLETS(DACOMITINIB)
ClinicalTrials.gov Identifier (NCT): NCT03865446
Protocol ID: A7471058
    Share
PrintDownload
Open Plain Language Summary Result: Click here